Table 1 Patients characteristics

Age median (range)

72 (56–83)

70 (57–83)

0.216*

PSA (ng/mL) median range

6.5 (3.7-31.8)

7.2 (3.5-17.7)

0.421*

Duration of NeoADT (month) median (range)

4 (2–43)

4 (1–34)

0.640*

Prostate volume (mL) at impant median (range)

26 (8–42)

27 (10–48)

0.187*

IPSS at baseline median (range)

6 (0–17)

7 (0–23)

0.132*

OABSS at baseline median (range)

3 (0–8)

3 (0–10)

0.343*

No of needle/seeds median (range)

22 (15–30)/60 (40–90)

22 (16–30)/65 (35–90)

0.304/0.128*

Total activity (MBq) median (range)

875 (449–1314)

876 (438–1314)

0.221*

Stage T1c/T2a/T2b/T2c/T3a

38/25/6/1/0

37/28/4/1/1

0.813^†

Gleason score −6/7/8-10

44/24/2

45/24/2

0.648^†

Neoadjuvant ADT yes/no

20/50

21/50

1.000^†

EBRT yes/no

17/53

17/54

1.000^†

Pre use of alpha-1 antagonist yes/no

12/58

10/61

0.649^†